Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Anti-osteoporosis treatment was compared with placebo, calcium, vitamin D, or combination of calcium and vitamin D for most of the studies, while active comparators were seldom observed in the control.

Source: Study Characteristics. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Systematic review.

Systematic review

Uses explicit methods to identify, assess and summarise research on a defined question.

Meta-analysis reported · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

An Updated Systematic Review With Meta-Analysis of Clinical Trials

Source: Article title.

An Updated Systematic Review With Meta-Analysis of Clinical Trials

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials

Systematic review · Frontiers in Pharmacology · 2019

Original publication title

Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials

Ling-Feng Zeng; Bi-Qi Pan; Gui-Hong Liang; Ming-Hui Luo; Ye Cao; Da Guo; Hong-Yun Chen; Jian-Ke Pan; He-Tao Huang; Qiang Liu; Zi-Tong Guan; Yan-Hong Han; Di Zhao; Jin-Long Zhao; Sen-Rong Hou; Ming Wu; Jiong-Tong Lin; Jia-Hui Li; Wei-Xiong Liang; Ai-Hua Ou; Qi Wang; Wei-Yi Yang; Jun Liu

Copyright © 2019 Zeng, Pan, Liang, Luo, Cao, Guo, Chen, Pan, Huang, Liu, Guan, Han, Zhao, Zhao, Hou, Wu, Lin, Li, Liang, Ou, Wang, Yang and Liu

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Conclusions:

This systematic review confirms that bisphosphonates were connected with a decreased risk of vertebral fractures, nonvertebral fractures, and clinical fractures for male subjects with osteoporosis. Future research is needed to further elucidate the role of nonbisphosphonates in treating fractures of osteoporosis subjects.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

The aim of this study was to evaluate the correlation between anti-osteoporosis medication and the risk of fracture in relation to low bone mass [including outcomes of osteoporosis, fracture, and bone mineral density (BMD) loss] in male subjects analyzed in studies within the updated literature.

Source: Objective:

Abstract: What methods does the paper describe?

Randomized controlled trials (RCTs) that analyzed the effectiveness of a treating prescription for male subjects with osteoporosis (or low BMD) and that focused on the outcomes of fracture were included. Relevant studies from Embase, Web of Science, PubMed, and Chinese database of CNKI were retrieved from inception to January 30th, 2019. Two staff members carried out the eligibility assessment and data extraction. The discrepancies were settled by consultation with another researcher. We calculated the pooled relative risks (RRs) based on 95% confidence intervals (CIs).

Source: Methods:

Abstract: Results

Twenty-seven documents (28 studies) with 5,678 subjects were identified. For the category of bisphosphonates, significant results were observed in pooled analyses for decreased risk of the vertebral fracture domain (RR, 0.44 [95% CI, 0.31 to 0.62]), nonvertebral fracture domain (RR, 0.63 [95% CI, 0.46 to 0.87]), and clinical fracture domain (RR, 0.59 [95% CI, 0.48 to 0.72]) compared with those of controls. Participants with bisphosphonates had a 56% (95% CI = 38 to 69%) lower risk of vertebral fractures, 37% (95% CI = 13 to 54%) lower risk of nonvertebral fractures, and 41% (95% CI = 28 to 52%) lower risk of clinical fractures. Furthermore, meta-analyses also demonstrated a decreased risk of the vertebral fracture domain via treatment with risedronate (RR, 0.45 [95% CI, 0.28 to 0.72]) and alendronate (RR, 0.41 [95% CI, 0.23 to 0.74]), but not with calcitriol, calcitonin, denosumab, ibandronate, monofluorophosphate, strontium ranelate, teriparatide, or zoledronic acid, compared with that of controls.

Source: Results:

Abstract: Conclusions

This systematic review confirms that bisphosphonates were connected with a decreased risk of vertebral fractures, nonvertebral fractures, and clinical fractures for male subjects with osteoporosis. Future research is needed to further elucidate the role of nonbisphosphonates in treating fractures of osteoporosis subjects.

Source: Conclusions:
Authors’ abstract

Background:

Several epidemiological articles have reported the correlations between anti-osteoporosis medication and the risks of fractures in male and female subjects, but the specific efficacy of anti-osteoporosis medication for male subjects remains largely unexplored.

Objective:

The aim of this study was to evaluate the correlation between anti-osteoporosis medication and the risk of fracture in relation to low bone mass [including outcomes of osteoporosis, fracture, and bone mineral density (BMD) loss] in male subjects analyzed in studies within the updated literature.

Methods:

Randomized controlled trials (RCTs) that analyzed the effectiveness of a treating prescription for male subjects with osteoporosis (or low BMD) and that focused on the outcomes of fracture were included. Relevant studies from Embase, Web of Science, PubMed, and Chinese database of CNKI were retrieved from inception to January 30th, 2019. Two staff members carried out the eligibility assessment and data extraction. The discrepancies were settled by consultation with another researcher. We calculated the pooled relative risks (RRs) based on 95% confidence intervals (CIs).

Results:

Twenty-seven documents (28 studies) with 5,678 subjects were identified. For the category of bisphosphonates, significant results were observed in pooled analyses for decreased risk of the vertebral fracture domain (RR, 0.44 [95% CI, 0.31 to 0.62]), nonvertebral fracture domain (RR, 0.63 [95% CI, 0.46 to 0.87]), and clinical fracture domain (RR, 0.59 [95% CI, 0.48 to 0.72]) compared with those of controls. Participants with bisphosphonates had a 56% (95% CI = 38 to 69%) lower risk of vertebral fractures, 37% (95% CI = 13 to 54%) lower risk of nonvertebral fractures, and 41% (95% CI = 28 to 52%) lower risk of clinical fractures. Furthermore, meta-analyses also demonstrated a decreased risk of the vertebral fracture domain via treatment with risedronate (RR, 0.45 [95% CI, 0.28 to 0.72]) and alendronate (RR, 0.41 [95% CI, 0.23 to 0.74]), but not with calcitriol, calcitonin, denosumab, ibandronate, monofluorophosphate, strontium ranelate, teriparatide, or zoledronic acid, compared with that of controls.

Conclusions:

This systematic review confirms that bisphosphonates were connected with a decreased risk of vertebral fractures, nonvertebral fractures, and clinical fractures for male subjects with osteoporosis. Future research is needed to further elucidate the role of nonbisphosphonates in treating fractures of osteoporosis subjects.

Publication and source details

Original title: Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical Trials

Ling-Feng Zeng; Bi-Qi Pan; Gui-Hong Liang; Ming-Hui Luo; Ye Cao; Da Guo; Hong-Yun Chen; Jian-Ke Pan; He-Tao Huang; Qiang Liu; Zi-Tong Guan; Yan-Hong Han; Di Zhao; Jin-Long Zhao; Sen-Rong Hou; Ming Wu; Jiong-Tong Lin; Jia-Hui Li; Wei-Xiong Liang; Ai-Hua Ou; Qi Wang; Wei-Yi Yang; Jun Liu

Frontiers in Pharmacology · 2019

Edited by: Amanj Kurdi, University of Strathclyde, United Kingdom

Reviewed by: Yaser Mohammed Al-Worafi, Ajman University of Science and Technology, United Arab Emirates; Raja Ahsan Aftab, Taylor’s University, Malaysia; Li Shean Toh, University of Nottingham, United Kingdom; Natalie McFadyen Weir, University of Strathclyde, United Kingdom; Natalie Schellack, Sefako Makgatho Health Sciences University, South Africa

*Correspondence: Jun Liu, liujungdtcm@163.com ; Wei-Yi Yang, yangwy002@163.com

This article was submitted to Pharmaceutical Medicine and Outcomes Research, a section of the journal Frontiers in Pharmacology

†These authors have contributed equally to this work.

Copyright © 2019 Zeng, Pan, Liang, Luo, Cao, Guo, Chen, Pan, Huang, Liu, Guan, Han, Zhao, Zhao, Hou, Wu, Lin, Li, Liang, Ou, Wang, Yang and Liu2019Zeng, Pan, Liang, Luo, Cao, Guo, Chen, Pan, Huang, Liu, Guan, Han, Zhao, Zhao, Hou, Wu, Lin, Li, Liang, Ou, Wang, Yang and Liuhttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T19:16:54.969006+00:00

DOI: 10.3389/fphar.2019.00882 · PMC6695469